Full-Time
Equity crowdfunding platform for startup investments
No salary listed
Austin, TX, USA
Hybrid
| , |
MicroVentures runs an equity crowdfunding platform within the fintech space. It lets both accredited and non-accredited investors invest in high-growth startups and private-market opportunities that were once only available to venture funds and institutions. The platform handles the investment process online and charges fees on both sides: investors incur fees based on their investment amount, while companies pay listing fees to run fundraising campaigns. It also provides educational resources to help investors understand equity crowdfunding risks. Compared with competitors, MicroVentures differentiates itself by enabling participation from non-accredited investors and by supporting a dual-fee model on the platform. The company’s goal is to connect a broad range of investors with early-stage opportunities in private markets and to facilitate funding for startups through its online marketplace.
Company Size
51-200
Company Stage
Seed
Total Funding
$1.5M
Headquarters
Austin, Texas
Founded
2009
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Company Equity
Performance Bonus
Oakland-based Mighty Buildings, which is on a quest to build homes using 3D printing, robotics and automation, has raised a $22 million extension to its Series B round of funding. The company claims to be able to 3D print structures “two times as quickly with 95% less labor hours and 10-times less waste” than conventional construction. For example, it says it can 3D print a 350-square-foot studio apartment in just 24 hours.
3D Printed Biodegradable Mesh Designed to Deliver Cancer Drugs Directly to Tumor Site With Greater Efficacy, Reduced Side Effects
ICON, in one of the largest seed rounds for Texas start-ups in 2018, announces $9M in funding.
Rochester, MN | February 10, 2023 – Pneumeric Inc., developers of the Capnospot™ - A disposable medical device that allows visual detection of carbon dioxide during treatment of a collapsed lung with needle decompression, has raised nearly $40,000 from 124 investors through its recently launched equity crowdfunding campaign. These funds build on the $1.2 million Pneumeric has
BOSTON, Aug. 15, 2022 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium's lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels. Potential to reverse years of age-related cartilage loss Tweet this We believe that any disease can be cured. - Remedium Bio